Law360, New York (September 20, 2012, 3:19 PM EDT) -- Bisphenol A (BPA), one of the so-called endocrine disrupters, has been the target of continued legislative and regulatory action, and the federal government has devoted tens of millions of dollars toward its study. This brief article summarizes events from the last few years, showing how, in my opinion, a useful product can be denigrated by poor science and virtually marginalized out of existence.
Legislative and Regulatory Activities
In October 2008, the Natural Resources Defense Council started the ball rolling by filing a citizen petition requesting that...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.